ReviewVaccines2021
COVID-19 Vaccines in Cancer Patients. Seropositivity and Safety. Systematic Review and Meta-Analysis.
Review in Vaccines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- COVID-19 vaccination in patients with cancer receiving immune checkpoint inhibitors: a systematic review and meta-analysis.Journal for immunotherapy of cancer · 2023Pooled it
- COVID-19 vaccine acceptance and hesitancy among patients with cancer: a systematic review and meta-analysis.Public health · 2022Pooled it
- COVID-19 vaccine response and safety in patients with cancer: An overview of systematic reviews.Frontiers in public health · 2022Pooled it
- Efficacy and safety profile of COVID-19 mRNA vaccine in patients with hematological malignancies: Systematic review and meta-analysis.Frontiers in oncology · 2022Pooled it
- Neutralizing antibody responses to three XBB protein vaccines in older adults.Signal transduction and targeted therapy · 2025Article
- Vaccine responses and hybrid immunity in people living with HIV after SARS-CoV-2 breakthrough infections.NPJ vaccines · 2024Article
- Plasma EV-miRNAs as Potential Biomarkers of COVID-19 Vaccine Immune Response in Cancer Patients.Vaccines · 2024Article
- Real-World Assessment of Recommended COVID-19 Vaccination Waiting Period after Chemotherapy.Vaccines · 2024Article
- Hesitant or not: A cross-sectional study of socio-demographics, conspiracy theories, trust in public health information, social capital and vaccine hesitancy among older adults in Ghana.Human vaccines & immunotherapeutics · 2023Article
- Exploring hematic crasis variations in cancer patients following SARS-CoV-2 vaccination: a real-practice study.Infectious agents and cancer · 2023Article
- Concerns related to the interactions between COVID-19 vaccination and cancer/cancer treatment were barriers to complete primary vaccination series among Chinese cancer patients: A multicentre cross-sectional survey.Human vaccines & immunotherapeutics · 2023Article
- Article
- Cancer Patients during COVID-19 Pandemic: A Mini-Review.Healthcare (Basel, Switzerland) · 2023Review
- Article
- Global caregiver perspectives on COVID-19 immunization in childhood cancer: A qualitative study.Frontiers in public health · 2023Article
- A comparative study of the COVID-19 vaccine efficacy among cancer patients: mRNA versus non-mRNA.PloS one · 2023Article
- Effect of the number of coronavirus disease 2019 (COVID-19) vaccination shots on the occurrence of pneumonia, severe pneumonia, and death in SARS-CoV-2-infected patients.Frontiers in public health · 2023Article
- Higher COVID-19 Vaccination Rates Are Associated with Lower COVID-19 Mortality: A Global Analysis.Vaccines · 2022Article
- COVID-19 and Cancer Patients in the Second Year of the Pandemic: Investigating Treatment Impact, Information Sources, and COVID-19-Related Knowledge, Attitudes and Practices.Current oncology (Toronto, Ont.) · 2022Article
- Efficacy of COVID-19 Booster Vaccines in Patients with Hematologic Malignancies: Experiences in a Real-World Scenario.Cancers · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with cancer are among the most vulnerable groups of the COVID-19 pandemic, whereas vaccinations can represent a cornerstone in overcoming the pandemic itself. However, cancer patients were excluded from clinical trials for COVID-19 vaccinations, and thus the data on the immunogenicity and safety of COVID-19 vaccines in cancer patients are limited. In this systematic review, we assessed the seroconversion rate and the safety of COVID-19 vaccinations in cancer patients. We searched a bibliographic database up until 31 July 2021. Utilizing inclusion criteria, six studies were selected and analyzed for this meta-analysis. This included 621 cancer patients and 256 controls. Results show that patients with solid tumors show adequate antibody responses (>90%), though the antibody titers were significantly lower than those of healthy controls. Similarly, a significantly lower rate of seroconversion was registered in patients with hematologic malignances. The vaccines showed a good safety profile; no grade 3-4 adverse events were registered. This review demonstrates generally high immunogenicity from COVID-19 vaccines in patients with cancer, with better results for solid tumors than hematological malignances, and with a good safety profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.